NCT07160231View on ClinicalTrials.gov

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2028

Conditions
Rheumatoid Arthritis (RA)Psoriatic Arthritis (PsA)Axial Spondyloarthritis (AxSpA)
Interventions
DRUG

JAKi dose reduction strategy

JAKi dose reduction strategy

DRUG

JAKi disease activity guided continuation of same dose strategy

JAKi disease activity guided continuation of same dose strategy

Trial Locations (7)

6574 NA

RECRUITING

Sint Maartenskliniek Nijmegen, Nijmegen

6229 HX

NOT_YET_RECRUITING

Maastricht UMC+, Maastricht

5022 GC

NOT_YET_RECRUITING

Elisabeth-TweeSteden Ziekenhuis Tilburg, Tilburg

7512 KZ

NOT_YET_RECRUITING

Medisch Spectrum Twente, Enschede

8025 AB

NOT_YET_RECRUITING

Isala Zwolle, Zwolle

3015 GD

NOT_YET_RECRUITING

Erasmus MC, Rotterdam

3079 DZ

NOT_YET_RECRUITING

Maasstad ziekenhuis, Rotterdam

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Sint Maartenskliniek

OTHER